Although there is still a lack of consensus on standard of care for EGFR-TKI resistant NSCLC patients who developed MET amplification after the failure of EGFR-TKI due to the absence of robust evidences, the reciprocal crosstalk between EGFR and MET suggests that simultaneous inhibition of these two targets would enhance the clinical benefit of patients with concurrent EGFR and MET aberrations. Here, MET is linked to non-small cell lung carcinoma.